Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 150

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 1
Chunk 150
---
, many countries limit the enforceability of patents against government agencies or government contractors. In those
countries, we may have limited remedies, which could materially diminish the value of those patents. This could limit our potential revenue
opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant
commercial advantage from the intellectual property that we develop or license.

If we are unable to protect the confidentiality of any trade
secrets, our business and competitive position would be harmed.

In addition to seeking patents for any product candidates, we may rely
on trade secrets, including know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect
this information, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them,
such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other
third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants.

Because we rely and expect to continue to rely on third parties to
manufacture our product candidates and future product candidates, and we collaborate and expect to continue to collaborate with third
parties on the development of current and future product candidates, we must, at times, share trade secrets with them. If we conduct joint
research and development programs, we may be required to share trade secrets under the terms of our research and development partnerships
or similar agreements. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable,
material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors
and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the
third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed
when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade
secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation
of these agreements. Any disclosure, either intentional or unintentional, by our employees, the employees of third parties with whom we
share facilities or third-party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities,
or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary information could enable
competitors to duplicate or surpass